BeiGene
NASDAQ:BGNEBiotechBeijing, China, China · Est. 2010 · 7,000 employees
BeiGene is a Chinese biotechnology company developing innovative oncology and hematology treatments for both Western and Chinese markets.
16
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
21
Indications↗
Distinct diseases across all programs
149
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
16 drugs in development
Phase 32
Phase 29
Phase 110
Preclinical3
By Therapeutic Area
top 2
Oncology
1594%
Immunology
16%
R&D Momentum
60/100
Pipeline Velocity
15/100
Trial Completion Rate
86/100
Pipeline Concentration
88/100
Pipeline Freshness
62/100
Strategic Signals
- ↗Active in Immunology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Jul 14, 2026
Recruiting
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies
Jul 14, 2026
Active, not recruiting
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor BGB-11417 in Adult Patients With Mature B-cell Malignancies
Jul 11, 2026
Recruiting
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Jul 11, 2026
Recruiting
A Single-Arm, Multi-Center, Open-Label, Phase 2 Study to Evaluate Efficacy and Safety of Tislelizumab (BGB-A317), an Anti-PD-1 Monoclonal Antibody, as Monotherapy in Patients With Previously-Treated Locally Advanced Unresectable or Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors
Jul 9, 2026
Recruiting
A Phase 1, Open-Label Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B455 in Patients With Selected Advanced or Metastatic Solid Tumors
Jul 9, 2026
Terminated
A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combinations in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplifications
Jul 1, 2026
Active, not recruiting
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
4 more events
Jun 24, 2026TrialPhase 1a/1b Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and Its Safety and Tolerability in Patients With Autoimmune Dermatological Diseases
Jun 24, 2026TrialA Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies
Jun 24, 2026TrialA Phase 3, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of Either Cisplatin or Carboplatin +Gemcitabine + Tislelizumab Compared With Either Cisplatin or Carboplatin + Gemcitabine + Placebo as First-line Treatment for Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Mar 20, 2026TrialALPINE-3: Zanubrutinib First-Line CLL
Details
Company Info
Company Overview
$18.0B
Mkt Cap
$1.5B
Revenue
—
Cash
CEOJohn V. Oyler
Founded2010
Employees7,000
HQBeijing, China, China
ExchangeNASDAQ:BGNE
Websitebeigene.com
LinkedInCompany Page
Therapeutic Focus
OncologyOtherGastroenterologyNephrologyInfectious DiseaseRespiratoryHematologyImmunology
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Immunology(1 drug)
—
1
1
—
—
Immunology(1 drug)
Oncology(15 drugs)
3
9
8
2
—
Oncology(15 drugs)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)